Updates: 24.04.2021 01:55
Published: 24.04.2021, 01:55
WASHINGTON – The United States will resume vaccination with the Govit-19 vaccine from Johnson & Johnson (J&J). The decision was made by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). The vaccine was discontinued ten days ago because it combined with rare but dangerous blood clots. It can be recovered immediately.
In a joint statement, the two officials said health systems and vaccinated recipients would be alerted to the risk of a serious syndrome involving a severe blood clot and a reduction in platelet counts.
The decision comes shortly after CDC consultants recommended stopping ten to four vaccination intervals from J&J. This was preceded by an investigation into the risks associated with the vaccine by agencies. The advisory panel also confirmed the current FDA approval that the vaccine can be given to people over 18, and said the benefits outweigh the risks.
The vaccine was discontinued by the J&J vaccine on April 13, and a few days after its administration there were rare reports of blood clotting problems in people who had been vaccinated. To date, nearly seven million vaccines have been administered in the United States.
The vaccine was approved by J&J for emergency use in the United States at the end of February, giving it a dose that raises high expectations and is easy to store. So far, however, this product makes up a small fraction of the US vaccines. The U.S. received only nine million doses from the manufacturer, promising 100 million by the end of May.
The European Medicines Agency (EMA) said last week that it had found a link between the occurrence of blood clots and, in rare cases, the J&J vaccine. However, he added that the benefits of the vaccine outweigh its risks. In the Czech Republic, the first dose of the vaccine began to be given to general practitioners on Thursday.
“Coffee trailblazer. Social media ninja. Unapologetic web guru. Friendly music fan. Alcohol fanatic.”